The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Although we have come a long way in our understanding of the signals that drive cancer
growth, and how these signals can be targeted, effective control of this disease remains a …

Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib
combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD …

Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …